488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

• Omid Hamid,
• Lilian Siu,
• Dawn Baxter,
• Rachael Easton

Affiliations

Omid Hamid

Cedars-Sinai Medical Center Angeles Clinic and Research Institute, Santa Monica, California, USA

Lilian Siu

2Princess Margaret Cancer Centre, Toronto, Canada

Dawn Baxter

2GlaxoSmithKline, Philadelphia, PA, USA

Rachael Easton

2GlaxoSmithKline, Philadelphia, PA, USA